IDH1 mutations (e.g., R132H) produce the oncometabolite 2-hydroxyglutarate (2-HG), which impairs mitochondrial respiration and lowers the threshold for apoptosis; as a result, IDH1-mutant AML cells are selectively sensitive to BCL-2 inhibition [30]. Here, BCL2 is linked to acute myeloid leukemia.